Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 133.66 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Neurocrine Bioscienc Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides April 16, 2024 From Sentia Medical Sciences, Inc. Via GlobeNewswire The 5 Stocks Most Sold By Insiders This Year April 16, 2024 Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. Via MarketBeat Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. Via MarketBeat Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides February 14, 2023 From Sentia Medical Sciences, Inc. Via GlobeNewswire Pliant Therapeutics Gaps 34% Higher: More Upside To Come? January 25, 2023 Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. Via MarketBeat Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? November 11, 2022 Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. Via MarketBeat Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors September 29, 2022 Via AB Newswire Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027 May 05, 2021 Via FinancialNewsMedia Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry April 22, 2021 Via FinancialNewsMedia Exposures COVID-19 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.